A detailed history of Essex Financial Services, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Essex Financial Services, Inc. holds 956 shares of VRTX stock, worth $480,342. This represents 0.02% of its overall portfolio holdings.

Number of Shares
956
Previous 737 29.72%
Holding current value
$480,342
Previous $345,000 28.7%
% of portfolio
0.02%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$460.0 - $505.78 $100,740 - $110,765
219 Added 29.72%
956 $444,000
Q2 2024

Aug 09, 2024

BUY
$392.81 - $485.53 $10,605 - $13,109
27 Added 3.8%
737 $345,000
Q2 2024

Jul 31, 2024

BUY
$392.81 - $485.53 $12,962 - $16,022
33 Added 4.87%
710 $332,000
Q1 2024

Apr 23, 2024

BUY
$407.69 - $446.08 $15,084 - $16,504
37 Added 5.78%
677 $282,000
Q4 2023

Feb 05, 2024

SELL
$343.0 - $410.68 $3,773 - $4,517
-11 Reduced 1.69%
640 $260,000
Q3 2023

Nov 15, 2023

SELL
$338.18 - $362.46 $3,043 - $3,262
-9 Reduced 1.36%
651 $226,000
Q2 2023

Aug 08, 2023

SELL
$314.42 - $351.91 $6,602 - $7,390
-21 Reduced 3.08%
660 $232,000
Q1 2023

May 11, 2023

SELL
$283.23 - $323.1 $14,727 - $16,801
-52 Reduced 7.09%
681 $214,000
Q4 2022

Feb 10, 2023

BUY
$285.76 - $321.48 $3,143 - $3,536
11 Added 1.52%
733 $211,000
Q3 2022

Nov 07, 2022

SELL
$273.83 - $305.53 $7,119 - $7,943
-26 Reduced 3.48%
722 $209,000
Q2 2022

Aug 01, 2022

SELL
$234.96 - $292.55 $17,856 - $22,233
-76 Reduced 9.22%
748 $211,000
Q1 2022

Apr 21, 2022

BUY
$221.42 - $260.97 $182,450 - $215,039
824 New
824 $215,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Essex Financial Services, Inc. Portfolio

Follow Essex Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Essex Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Essex Financial Services, Inc. with notifications on news.